ARWR (Arrowhead Pharmaceuticals) Short-Term Debt: $40.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARWR Arrowhead Pharmaceuticals Inc ARWR
53 GF Score
Price $71.91
GF Value $50.53
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Short-Term Debt?

Arrowhead Pharmaceuticals ARWR -0.01% 53 Short-Term Debt is $40.0 Mil as of Mar. 2026. GuruFocus rates ARWR with a GF Score™ of 53/100 and a GF Value™ of $50.53 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Arrowhead Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was $40.0 Mil.

Arrowhead Pharmaceuticals's quarterly Short-Term Debt stayed the same from Sep. 2025 ($40.0 Mil) to Dec. 2025 ($40.0 Mil) and stayed the same from Dec. 2025 ($40.0 Mil) to Mar. 2026 ($40.0 Mil).

Arrowhead Pharmaceuticals's annual Short-Term Debt stayed the same from Sep. 2023 ($0.0 Mil) to Sep. 2024 ($0.0 Mil) but then increased from Sep. 2024 ($0.0 Mil) to Sep. 2025 ($40.0 Mil).

Arrowhead Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Arrowhead Pharmaceuticals Short-Term Debt Related Terms

Arrowhead Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Short-Term Debt Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 40.00

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.00 40.00 40.00 40.00 40.00
ARWR
53GF Score
Arrowhead Pharmaceuticals Inc ARWR
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $40.0 Mil mean?
Arrowhead Pharmaceuticals (ARWR) has a Short-Term Debt of $40.0 Mil as of Mar. 2026.
Is Arrowhead Pharmaceuticals' Short-Term Debt too high?
Arrowhead Pharmaceuticals' current Short-Term Debt is $40.0 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Short-Term Debt compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Short-Term Debt of $40.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Arrowhead Pharmaceuticals's current Short-Term Debt is $40.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $50.53, compared to a current price of $71.91 — trading 42.3% above its estimated fair value. The current Short-Term Debt is $40.0 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Short-Term Debt is $40.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $71.91 is trading 42.3% above its estimated GF Value™ of $50.53. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Short-Term Debt: $40.0 Mil
  • GF Value™: $50.53 vs. price of $71.91 (42.3% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
53GF Score

Get the complete analysis for ARWR

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.91
Price
$50.53
GF Value